Scopoletin
Based on 4 publication(s) in Google Scholar
Scopoletin is an inhibitor of acetylcholinesterase (AChE).
For research use only. We do not sell to patients.
- Purity: 99.89%
- CAS No.: 92-61-5
- Formula: C10H8O4
- Molecular Weight:192.17
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Scopoletin
More-
RT-PCR
-
ELISA
-
Apoptosis Analysis
-
WB
-
IF
Biological Activity
|
AChE |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-431 | IC50 |
>100 μM
Compound: Sco, Scopoletin
|
Cytotoxicity against human A431 cells after 24 hrs by MTT assay
Cytotoxicity against human A431 cells after 24 hrs by MTT assay
|
[PMID: 23218780] |
| A549 | IC50 |
>100 μM
Compound: Sco, Scopoletin
|
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
|
[PMID: 23218780] |
| A549 | IC50 |
>20 μg/mL
Compound: 14
|
Cytotoxicity against human A549 cells
Cytotoxicity against human A549 cells
|
[PMID: 23511021] |
| A549 | IC50 |
>30 μM
Compound: 6, Scopoletin
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 25703298] |
| A549 | IC50 |
>25 μM
Compound: Scopoletin
|
Anticancer activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
Anticancer activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
|
[PMID: 32438251] |
| BXPC-3 | IC50 |
>100 μM
Compound: Sco, Scopoletin
|
Cytotoxicity against human BxPC3 cells after 24 hrs by MTT assay
Cytotoxicity against human BxPC3 cells after 24 hrs by MTT assay
|
[PMID: 23218780] |
| DU-145 | IC50 |
>50 μM
Compound: scopoletin
|
Cytotoxicity against human DU145
Cytotoxicity against human DU145
|
[PMID: 16038556] |
| HCT-116 | IC50 |
>100 μM
Compound: Sco, Scopoletin
|
Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
|
[PMID: 23218780] |
| HCT-116 | IC50 |
>30 μM
Compound: 6, Scopoletin
|
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 25703298] |
| HCT-116 | IC50 |
>25 μM
Compound: Scopoletin
|
Growth inhibition of human HCT116 cells after 48 hrs by MTT assay
Growth inhibition of human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 27956344] |
| HeLa | IC50 |
>80 μM
Compound: Scopoletin
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay
|
[PMID: 36242987] |
| Hep 3B2 | IC50 |
>13.23 μg/mL
Compound: 14
|
Cytotoxicity against human Hep3B cells
Cytotoxicity against human Hep3B cells
|
[PMID: 23511021] |
| HepG2 | IC50 |
>50 μM
Compound: scopoletin
|
Cytotoxicity against human HepG2
Cytotoxicity against human HepG2
|
[PMID: 16038556] |
| HepG2 | IC50 |
>100 μM
Compound: Sco, Scopoletin
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 23218780] |
| HepG2 | IC50 |
>20 μg/mL
Compound: 14
|
Cytotoxicity against human HepG2 cells
Cytotoxicity against human HepG2 cells
|
[PMID: 23511021] |
| HepG2 | IC50 |
>25 μM
Compound: Scopoletin
|
Anticancer activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
Anticancer activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
|
[PMID: 32438251] |
| HL-60 | IC50 |
9.5 μM
Compound: 3
|
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
|
[PMID: 15387667] |
| HL-60 | IC50 |
>50 μM
Compound: scopoletin
|
Cytotoxicity against human HL60
Cytotoxicity against human HL60
|
[PMID: 16038556] |
| HL-60 | IC50 |
>100 μM
Compound: Sco, Scopoletin
|
Cytotoxicity against human HL60 cells after 24 hrs by MTT assay
Cytotoxicity against human HL60 cells after 24 hrs by MTT assay
|
[PMID: 23218780] |
| HT-1080 | IC50 |
12.5 μM
Compound: 3
|
Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
|
[PMID: 15387667] |
| HT-29 | IC50 |
>100 μM
Compound: 7, scopoletin
|
Antiproliferative activity against human HT-29 cells after 72 hrs by crystal violet staining method
Antiproliferative activity against human HT-29 cells after 72 hrs by crystal violet staining method
|
[PMID: 22765897] |
| HT-29 | ED50 |
>10 μM
Compound: scopoletin
|
Cytotoxicity against human HT-29 cells
Cytotoxicity against human HT-29 cells
|
[PMID: 23301897] |
| Huh-7 | IC50 |
>25 μM
Compound: Scopoletin
|
Growth inhibition of human HuH7 cells after 48 hrs by MTT assay
Growth inhibition of human HuH7 cells after 48 hrs by MTT assay
|
[PMID: 27956344] |
| HuT78 | IC50 |
>100 μM
Compound: Sco, Scopoletin
|
Cytotoxicity against human HUT78 cells after 24 hrs by MTT assay
Cytotoxicity against human HUT78 cells after 24 hrs by MTT assay
|
[PMID: 23218780] |
| HUVEC | ED50 |
>5 μg/mL
Compound: 7-hydroxy-6-methoxycoumarin
|
Cytotoxicity against HUVEC
Cytotoxicity against HUVEC
|
[PMID: 15043409] |
| HUVEC | ED50 |
>5 μg/mL
Compound: scopoletin
|
Cytotoxicity against human HUVEC
Cytotoxicity against human HUVEC
|
[PMID: 15270571] |
| HUVEC | ED50 |
>5 μg/mL
Compound: scopoletin
|
Cytotoxicity against HUVEC
Cytotoxicity against HUVEC
|
[PMID: 17190457] |
| K562 | IC50 |
>100 μM
Compound: Sco, Scopoletin
|
Cytotoxicity against human K562 cells after 24 hrs by MTT assay
Cytotoxicity against human K562 cells after 24 hrs by MTT assay
|
[PMID: 23218780] |
| KB | ED50 |
>5 μg/mL
Compound: scopoletin
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 15270571] |
| KB | IC50 |
4 μg/mL
Compound: Scopoltin
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 9214732] |
| L02 | IC50 |
>25 μM
Compound: Scopoletin
|
Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 32438251] |
| L6 | IC50 |
>90 μM
Compound: 4
|
Cytotoxicity against rat L6 cells after 72 hrs by microplate fluorimetry
Cytotoxicity against rat L6 cells after 72 hrs by microplate fluorimetry
|
[PMID: 21438586] |
| LNCaP | ED50 |
>5 μg/mL
Compound: 7-hydroxy-6-methoxycoumarin
|
Cytotoxicity against human LNCAP cells
Cytotoxicity against human LNCAP cells
|
[PMID: 15043409] |
| LNCaP | ED50 |
>5 μg/mL
Compound: scopoletin
|
Cytotoxicity against human LNCAP cells
Cytotoxicity against human LNCAP cells
|
[PMID: 15270571] |
| LNCaP | ED50 |
>5 μg/mL
Compound: scopoletin
|
Cytotoxicity against human LNCAP cells
Cytotoxicity against human LNCAP cells
|
[PMID: 17190457] |
| LoVo | IC50 |
18.5 μM
Compound: 3
|
Cytotoxicity against human doxorubicin-resistant LoVo cells after 72 hrs by MTT assay
Cytotoxicity against human doxorubicin-resistant LoVo cells after 72 hrs by MTT assay
|
[PMID: 15387667] |
| LoVo | IC50 |
7.3 μM
Compound: 3
|
Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
|
[PMID: 15387667] |
| Lu1 | ED50 |
>5 μg/mL
Compound: 7-hydroxy-6-methoxycoumarin
|
Cytotoxicity against human Lu1 cells
Cytotoxicity against human Lu1 cells
|
[PMID: 15043409] |
| Lu1 | ED50 |
>5 μg/mL
Compound: scopoletin
|
Cytotoxicity against human Lu1 cells
Cytotoxicity against human Lu1 cells
|
[PMID: 15270571] |
| Lu1 | ED50 |
>5 μg/mL
Compound: scopoletin
|
Cytotoxicity against human Lu1 cells
Cytotoxicity against human Lu1 cells
|
[PMID: 17190457] |
| Macrophage | IC50 |
5 μM
Compound: 4, scopoletin
|
Antiinflammatory activity in NMRI mouse macrophages assessed as inhibition of A23187-induced PGE2 release by Ellman's method
Antiinflammatory activity in NMRI mouse macrophages assessed as inhibition of A23187-induced PGE2 release by Ellman's method
|
[PMID: 8988605] |
| Macrophage | IC50 |
5 μmol
Compound: 4, scopoletin
|
Antiinflammatory activity in NMRI mouse macrophages assessed as inhibition of A23187-induced PGE2 release by Ellman's method
Antiinflammatory activity in NMRI mouse macrophages assessed as inhibition of A23187-induced PGE2 release by Ellman's method
|
[PMID: 8988605] |
| MCF-10A | IC50 |
>25 μM
Compound: Scopoletin
|
Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 34315044] |
| MCF7 | ED50 |
>5 μg/mL
Compound: 7-hydroxy-6-methoxycoumarin
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 15043409] |
| MCF7 | IC50 |
>50 μM
Compound: scopoletin
|
Cytotoxicity against human MCF7
Cytotoxicity against human MCF7
|
[PMID: 16038556] |
| MCF7 | ED50 |
>5 μg/mL
Compound: scopoletin
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 17190457] |
| MCF7 | IC50 |
>100 μM
Compound: 7, scopoletin
|
Antiproliferative activity against human MCF7 cells after 72 hrs by crystal violet staining method
Antiproliferative activity against human MCF7 cells after 72 hrs by crystal violet staining method
|
[PMID: 22765897] |
| MCF7 | IC50 |
17.11 μg/mL
Compound: 14
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 23511021] |
| MCF7 | IC50 |
>25 μM
Compound: Scopoletin
|
Anticancer activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
Anticancer activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
|
[PMID: 32438251] |
| MCF7 | IC50 |
>25 μM
Compound: Scopoletin
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
|
[PMID: 34315044] |
| MCF7 | IC50 |
>80 μM
Compound: Scopoletin
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay
|
[PMID: 36242987] |
| MDA-MB-231 | IC50 |
>100 μM
Compound: 7, scopoletin
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by crystal violet staining method
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by crystal violet staining method
|
[PMID: 22765897] |
| MDA-MB-231 | IC50 |
>100 μM
Compound: Sco, Scopoletin
|
Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
|
[PMID: 23218780] |
| MDA-MB-231 | IC50 |
>20 μg/mL
Compound: 14
|
Cytotoxicity against human MDA-MB-231 cells
Cytotoxicity against human MDA-MB-231 cells
|
[PMID: 23511021] |
| MDA-MB-231 | IC50 |
>30 μM
Compound: 6, Scopoletin
|
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 25703298] |
| MDA-MB-231 | IC50 |
>25 μM
Compound: Scopoletin
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
|
[PMID: 34315044] |
| MDA-MB-435 | IC50 |
>100 μM
Compound: Sco, Scopoletin
|
Cytotoxicity against human MDA-MB-435 cells after 24 hrs by MTT assay
Cytotoxicity against human MDA-MB-435 cells after 24 hrs by MTT assay
|
[PMID: 23218780] |
| MGC-803 | IC50 |
>80 μM
Compound: Scopoletin
|
Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay
|
[PMID: 36242987] |
| MKN-45 | IC50 |
>100 μM
Compound: Sco, Scopoletin
|
Cytotoxicity against human MKN45 cells after 24 hrs by MTT assay
Cytotoxicity against human MKN45 cells after 24 hrs by MTT assay
|
[PMID: 23218780] |
| NCI-H460 | IC50 |
>50 μM
Compound: scopoletin
|
Cytotoxicity against human NCI-H460
Cytotoxicity against human NCI-H460
|
[PMID: 16038556] |
| Neutrophil | IC50 |
>50 μM
Compound: 11
|
Antiinflammatory activity in human neutrophils assessed as inhibition of formyl-L-methionyl-L-leucyl-L-phenylalanine/cytochalasin B-induced elastase release
Antiinflammatory activity in human neutrophils assessed as inhibition of formyl-L-methionyl-L-leucyl-L-phenylalanine/cytochalasin B-induced elastase release
|
[PMID: 18211005] |
| Neutrophil | IC50 |
>50 μM
Compound: 11
|
Antiinflammatory activity in human neutrophils assessed as inhibition of formyl-L-methionyl-L-leucyl-L-phenylalanine/cytochalasin B-induced superoxide anion generation
Antiinflammatory activity in human neutrophils assessed as inhibition of formyl-L-methionyl-L-leucyl-L-phenylalanine/cytochalasin B-induced superoxide anion generation
|
[PMID: 18211005] |
| PANC-1 | IC50 |
>100 μM
Compound: Sco, Scopoletin
|
Cytotoxicity against human PANC1 cells after 24 hrs by MTT assay
Cytotoxicity against human PANC1 cells after 24 hrs by MTT assay
|
[PMID: 23218780] |
| PBMC | IC50 |
>100 μM
Compound: Sco, Scopoletin
|
Cytotoxicity against human PBMC after 24 hrs by MTT assay
Cytotoxicity against human PBMC after 24 hrs by MTT assay
|
[PMID: 23218780] |
| PC-3 | IC50 |
72.19 μM
Compound: Scopoletin
|
Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay
|
[PMID: 36242987] |
| Platelet | IC50 |
>50 μg/mL
Compound: Scopolatin
|
Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry
Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry
|
[PMID: 21106454] |
| Platelet | IC50 |
41.74 μg/mL
Compound: Scopolatin
|
Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry
Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry
|
[PMID: 21106454] |
| Sf21 | IC50 |
>100 μM
Compound: 7
|
Inhibition of human recombinant COX2 expressed in insect Sf21 cells by EIA assay
Inhibition of human recombinant COX2 expressed in insect Sf21 cells by EIA assay
|
[PMID: 17378609] |
| SK-MEL-28 | IC50 |
3.43 μM
Compound: 2
|
Anticancer activity against human SK-MEL-28 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Anticancer activity against human SK-MEL-28 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 37197457] |
| SK-MEL3 | IC50 |
1.5 μM
Compound: 2
|
Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 37197457] |
| SW-620 | IC50 |
>25 μM
Compound: Scopoletin
|
Growth inhibition of human SW620 cells after 48 hrs by MTT assay
Growth inhibition of human SW620 cells after 48 hrs by MTT assay
|
[PMID: 27956344] |
| U-937 | CC50 |
600.2 μM
Compound: 3
|
Cytotoxicity against human U937 cells by trypan blue assay after 48 hrs
Cytotoxicity against human U937 cells by trypan blue assay after 48 hrs
|
[PMID: 18060791] |
| U-937 | IC50 |
151.5 μM
Compound: 3
|
Growth inhibition of human U937 cells by [3H]thymidine incorporation assay
Growth inhibition of human U937 cells by [3H]thymidine incorporation assay
|
[PMID: 18060791] |
| U-937 | IC50 |
975.9 μM
Compound: 8
|
Antiproliferative activity against human U937 cells assessed as incorporation of [3H]-methyl-thymidine after 12 hrs by scintillation counting
Antiproliferative activity against human U937 cells assessed as incorporation of [3H]-methyl-thymidine after 12 hrs by scintillation counting
|
[PMID: 22925447] |
| U-937 | CC50 |
>2000 μM
Compound: 8
|
Cytotoxicity against human U937 cells after 48 hrs by trypan blue assay
Cytotoxicity against human U937 cells after 48 hrs by trypan blue assay
|
[PMID: 22925447] |
Scopoletin (SCT) is identified as a putative inhibitor of acetylcholinesterase (AChE). Scopoletin enhances the K+-stimulated release of ACh from rat frontal cortex synaptosomes, showing a bell-shaped dose effect curve (Emax: 4 μM) [1]. Scopoletin inhibits PC3 proliferation by inducing apoptosis of PC3 cells. The IC50 of Scopoletin for inhibiting PC3, PAA (human lung cancer cell), and Hela cell proliferation is (157±25), (154±51), and (294±100) mg/L, respectively. Scopoletin induces a marked time- and concentration-dependent inhibition of PC3 cell proliferation. Scopoletin reduces the protein content and decreases the acid phosphatase activity (ACP) level in PC3 cells in a concentration-dependent manner. Cells treated by Scopoletin show typical morphologic changes of apoptosis by light microscope, fluorescence microscope, and transmission electronmicroscope. Apoptosis rate is 0.3 %, 2.1 %, 9.3 % and 35 % for Scopoletin 0, 100, 200, and 400 mg/L, respectively, and cells in G2 phase decrease markedly after being treated with Scopoletin[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 92-61-5
-
Appearance Solid
-
Molecular Weight 192.17
-
Formula C10H8O4
-
Color White to yellow
-
SMILES
O=C1C=CC2=CC(OC)=C(O)C=C2O1
-
Synonyms
Gelseminic acid; Chrysatropic acid
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
Scopoletin alleviates cognitive deficits in 5xFAD mice via suppressing microglial inflammatory response. [Abstract]2026 Apr:153:157981. PMID: 41722121
Scopoletin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Apr:153:157981. [Abstract]
qPCR of Il6, Tnf, and Il1b in BV2 cells treated with LPS (100 ng/mL) and Scopoletin (SP, 10–50 μM).
Scopoletin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Apr:153:157981. [Abstract]
IL-6 and TNF-α in BV2 supernatants by ELISA treated with Scopoletin (SP, 50 μM).
-
Pestic Biochem Physiol
Mechanistic insights into chlorogenic acid and caffeic acid as novel juvenile hormone antagonists. [Abstract]2025 Dec:215:106655. PMID: 41162045 -
-
Oxid Med Cell Longev
Morinda citrifolia and Its Active Principle Scopoletin Mitigate Protein Aggregation and Neuronal Apoptosis through Augmenting the DJ-1/Nrf2/ARE Signaling Pathway. [Abstract]2019 May 2:2019:2761041. PMID: 31191797
Scopoletin purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2019 May 2:2019:2761041. [Abstract]
Rotenone-induced apoptosis is counteracted by Scopoletin (30 μM) in SH-SY5Y cells.
Scopoletin purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2019 May 2:2019:2761041. [Abstract]
Immunoblot analysis of several proteins involved in Nrf2/ARE pathway is performed in SH-SY5Y cells treated with/without Rotenone and Scopoletin (30 μM).
Scopoletin purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2019 May 2:2019:2761041. [Abstract]
Iba1 immunofluorescence treated with Scopoletin (SP, 50 μM).
Solvent & Solubility
DMSO : 62.5 mg/mL (325.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : < 1 mg/mL (insoluble)
* Scopoletin is usually formulated as a suspension.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (10.82 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (10.82 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
PC3 cells (5×107/L) 1 mL in exponential growth are seeded into four 24-well plates. The plates are incubated at 37°C in a humidified 5% CO2 atmospbee. After 24h, Scopoletin 33, 66, 133, 266, and 533 mg/L are added to wells (3 wells for each concentration for each plate). For control cells (3 wells foreach plate),only DMEM was added. The plates are incubated continually. The viable cells are counted by hemocytometer every day in the frist 4 d by Trypan blue dye exclusion method[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[1]
C56BL/6N male, 4-6-month-old and 16-18-month-old mice are used in the behavioral studies. The mice are housed in groups of four in cages at constant humidity (50-55%) and temperature (22±1°C) on a 12:12 h light/dark cycle (7:00–19:00 h), with food and water ad libitum. Younger mice (4-6 months) are implanted with i.c.v. cannulas for application of Scopolamine (SCOP) and Scopoletin. The aged mice are injected with Scopoletin by the s.c. route. Experiments are conducted between 8:00 and 16:00 h. Mice with i.c.v. cannulas are randomly divided into four experimental groups: vehicle; SCOP 20 μg; Scopoletin 2 μg; and SCOP 20 μg plus Scopoletin 2 μg. The drugs are applied in 1 μL of vehicle solution (SCOP: saline, Scopoletin: 3 DMSO: 7 sterile water). I.c.v. injections are carried out 15 min before the start of the tests. Aged mice obtained Scopoletin s.c. 30 min prior to object memory test (vehicle: 1 DMSO: 1 EtOH, diluted with olive oil as required)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Hornick A, et al. The coumarin Scopoletin potentiates acetylcholine release from synaptosomes, amplifies hippocampal long-term potentiation and ameliorates anticholinergic- and age-impaired memory. Neuroscience. 2011 Dec 1;197:280-92. [Content Brief]
[2]. Liu XL, et al. Effect of Scopoletin on PC3 cell proliferation and apoptosis. Acta Pharmacol Sin. 2001 Oct;22(10):929-33. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.2037 mL | 26.0186 mL | 52.0373 mL | 130.0931 mL |
| 5 mM | 1.0407 mL | 5.2037 mL | 10.4075 mL | 26.0186 mL | |
| 10 mM | 0.5204 mL | 2.6019 mL | 5.2037 mL | 13.0093 mL | |
| 15 mM | 0.3469 mL | 1.7346 mL | 3.4692 mL | 8.6729 mL | |
| 20 mM | 0.2602 mL | 1.3009 mL | 2.6019 mL | 6.5047 mL | |
| 25 mM | 0.2081 mL | 1.0407 mL | 2.0815 mL | 5.2037 mL | |
| 30 mM | 0.1735 mL | 0.8673 mL | 1.7346 mL | 4.3364 mL | |
| 40 mM | 0.1301 mL | 0.6505 mL | 1.3009 mL | 3.2523 mL | |
| 50 mM | 0.1041 mL | 0.5204 mL | 1.0407 mL | 2.6019 mL | |
| 60 mM | 0.0867 mL | 0.4336 mL | 0.8673 mL | 2.1682 mL | |
| 80 mM | 0.0650 mL | 0.3252 mL | 0.6505 mL | 1.6262 mL | |
| 100 mM | 0.0520 mL | 0.2602 mL | 0.5204 mL | 1.3009 mL |